Regimen curbs viral load in difficult-to-treat HCV

08/27/2013 | · MedPage Today (free registration)

Sofosbuvir plus rivabirin showed efficacy in reducing viral load in patients infected with hepatitis C who are considered unlikely to respond to treatment, data show. No deaths were recorded, and no patients stopped treatment due to adverse events. The study was conducted by researchers at the National Institute of Allergy and Infectious Diseases.

View Full Article in: · MedPage Today (free registration)

Published in Brief: